These advances in treatment have expanded treatment options and are expected to lead to improved outcomes in patients with chronic insomnia. Given the potential negative effects of chronic insomnia on patients, physicians’ knowledge of effective treatment strategies is important. Several recent advances have been made in nonpharmacological and pharmacological treatment options for chronic insomnia. Brief therapies for sleep disorders, stimulus control, sleep restriction therapy and relaxation therapy, and sleep hygiene (table) are all listed as possible treatment options.
QUVIVIQ is a prescription medicine for adults who have trouble falling asleep or staying asleep (insomnia).
Are there new treatments for sleep disorders?
The FDA has recommended that Dayvigo be classified as a controlled substance and this recommendation has been presented to the USA. Dayvigo also reported safety data over a 12-month period, making it the first FDA-approved sleep disorder medication to do so, according to Lynn Kramer, MD, chief clinical officer of the Neurology Business Group at Eisai. The decision to prescribe Dayvigo or another sleep aid to a patient with sleep disorders for whom CBT alone does not work depends on many individual factors for that patient and should be made with that patient, said Orbea. Here’s how it differs from other prescription sleep aids and what you should know about the risks.